Keyphrases
Small Cell Lung Cancer
100%
Temozolomide
14%
Olaparib
14%
Lung Cancer Progression
13%
Malignancy
12%
Patient-derived Xenograft
11%
Tumor
10%
Acquired Resistance
10%
Overall Survival
8%
New Therapeutic Strategies
8%
Therapeutic Vulnerabilities
8%
Extrachromosomal DNA
8%
Intratumoral Heterogeneity
8%
Cross-resistance
7%
Lineage-specific
7%
Therapeutic Target
7%
Non-small Cell Lung Cancer Cells
7%
DNA Damage Response
7%
Rapid Autopsy
6%
Subtype Heterogeneity
6%
Surveillance Epidemiology
6%
End Results Database
6%
DNA Amplification
6%
Proteomics
6%
SETD1A
6%
DNA Damage Repair
6%
Body Mass Index
6%
Epigenetics
6%
Chromatin Binding
6%
Database Analysis
6%
Cell-to-cell
6%
Translational Research
6%
Dereplication
6%
Induced Degradation
6%
Immune Gene Expression
6%
Chromatin
6%
Oncoprotein
6%
Chronic Myeloid Leukemia
6%
Targeted Drugs
6%
Cancer Initiating Cells
6%
Substrate Requirements
6%
Pulmonary Neuroendocrine Cells
6%
Guanosine Triphosphate
6%
Metabolic
6%
Functional Fidelity
6%
Cell Cycle Progression
6%
All-cause Mortality
6%
Lurbinectedin
6%
Non-cell Autonomous
6%
Tumor Immunity
6%
Biochemistry, Genetics and Molecular Biology
Cell Cycle
20%
Cyclin
20%
Proliferating Cell Nuclear Antigen
20%
Cancer Cell
17%
Cyclin-Dependent Kinase
16%
Tumor Progression
15%
Proteomics
14%
Myeloid
13%
Promoter Region
13%
Drive
13%
Carcinogenesis
13%
Overall Survival
12%
Transcription Factors
12%
ASCL1
12%
DNA Damage Response
10%
Single-Cell Analysis
10%
NEUROD1
10%
Neuroendocrine Cell
8%
Genetics
7%
Drug Resistance
7%
Poly ADP Ribose Polymerase
6%
Gene Amplification
6%
Drug Sensitivity
6%
Epigenetics
6%
Body Mass
6%
Mitotic Exit
6%
All Cause Mortality
6%
Genetically Engineered Mouse Strain
6%
Deoxyguanosine
6%
Clinical Research
6%
Guanosine Triphosphate
6%
Cross Resistance
6%
Tumor Immunity
6%
CTCF
6%
Methylation
6%
Gene Signature
6%
Enhancer Region
6%
Paralogy
6%
Mouse Model
6%
Telomere
6%
Cell Cycle Progression
6%
Gene Expression
6%
Drug Targeting
6%
Cell Cycle Arrest
6%
Hope
6%
Exome Sequencing
6%
Gene Locus
6%
Gene Regulatory Network
6%
SMARCA4
6%
SWI/SNF
6%
Medicine and Dentistry
Small Cell Lung Cancer
80%
Xenograft
22%
Neoplasm
19%
Temozolomide
16%
Olaparib
16%
Overall Survival
15%
Malignant Neoplasm
14%
Cancer
13%
Programmed Death 1 Ligand 1
13%
Non Small Cell Lung Cancer
13%
Durvalumab
13%
Extrachromosomal DNA
8%
Translational Research
8%
Cross Resistance
7%
Disease
7%
Cancer Cell
6%
Etoposide
6%
Surveillance, Epidemiology, and End Results
6%
Body Mass Index
6%
Gene Amplification
6%
Paralogy
6%
Proteomics
6%
Dihydroorotate Dehydrogenase
6%
DNA Repair
6%
All Cause Mortality
6%
Prostate Cancer
6%
Acute Myeloid Leukemia
6%
Treatment Response
6%
Chronic Myelogenous Leukemia
6%
Gene Expression
6%
Lurbinectedin
6%
DNA Synthesis
6%
Radiation Therapy
6%
Radiation Therapy
6%
Histone Demethylase
6%
Carcinoid
6%
Chromothripsis
6%
Cancer Growth
6%
Drive
6%
Cell Cycle
5%
Hazard Ratio
5%
Circulating Tumor Cell
5%
